reports
- GlobalData Healthcare Department
Zealand Pharma AS (ZEAL) - Financial Analysis Review
Zealand Pharma AS (ZEAL) - Financial Analysis Review Summary Zealand Pharma AS (Zealand) is a biotechnology company that discovers, designs and develops peptide based medicines that targets specialty diseases. The company’s marketed products comprise Lyxumia and Suliqua for the treatment of Type 2 diabetes and others for the treatment of obesity and for chemotherapeutic use. Zealand also offers proprietary pipeline drug candidates for the treatment of diabetes, short bowel syndrome, obesity;...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.